Argentine President tests positive for COVID-19 after vaccine

Alberto Fernández

Argentinian President, Alberto Fernández has tested positive for COVID-19 few months after receiving the Russian-made Sputnik V.

Fernández had said he would take the COVID-19 vaccine first, as a role model for the rest of Argentina.

In a series of tweets posted on Friday evening which was his birthday, the Argentinian President said a fever and slight headache had prompted him to get tested, CNN reports.

“I’m already isolated, complying with the current protocol and following the instructions of my personal doctor. I have contacted the people I met in the last 48 hours to assess whether they constitute close contact.”

An antigen test followed by a PCR test confirmed his COVID-19 diagnosis this weekend, according to Fernández medical team. The 62-year-old leader’s health remains “stable, asymptomatic, with parameters within normal ranges,” they said.

ALSO READ: 7 dead after receiving AstraZeneca vaccine in UK

Argentina became the first Latin American country to distribute the Sputnik V vaccine in late December, with the purchase of up to 25 million doses. Fernández received his first dose of that vaccine on January 21, and his second in February, a press officer at the Presidential Casa Rosada said.

It is possible to get infected and test positive for COVID-19 after being vaccinated. While vaccination reduces the likelihood of disease, especially severe cases, it is still unclear to what degree each coronavirus vaccine prevents all infections.

Russia’s Gamaleya Institute, which developed the Sputnik V vaccine, has wished Fernández well and emphasized the shot’s high protection against severe illness.

“We are sad to hear this. Sputnik V is 91.6 per cent effective against infection and 100 per cent effective against severe cases. If the infection is indeed confirmed and occurs, the vaccination ensures quick recovery without severe symptoms. We wish you a quick recovery!,” read a message on Sputnik V’s official Twitter account, citing rates published February in the medical journal The Lancet.